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Abstract
Background: Internationally, teledermatology has proven to be a viable alternative to conventional physical
referrals. Travel cost and referral times are reduced while patient safety is preserved. Especially patients from rural
areas benefit from this healthcare innovation. Despite these established facts and positive experiences from
EU neighboring countries like the Netherlands or the United Kingdom, Germany has not yet implemented
store-and-forward teledermatology in routine care.
Methods: The TeleDerm study will implement and evaluate store-and-forward teledermatology in 50 general
practitioner (GP) practices as an alternative to conventional referrals. TeleDerm aims to confirm that the possibility
of store-and-forward teledermatology in GP practices is going to lead to a 15% (n = 260) reduction in referrals in
the intervention arm. The study uses a cluster-randomized controlled trial design. Randomization is planned for the
cluster “county”. The main observational unit is the GP practice. Poisson distribution of referrals is assumed. The
evaluation of secondary outcomes like acceptance, enablers and barriers uses a mixed-methods design with
questionnaires and interviews.
Discussion: Due to the heterogeneity of GP practice organization, patient management software, information
technology service providers, GP personal technical affinity and training, we expect several challenges in
implementing teledermatology in German GP routine care. Therefore, we plan to recruit 30% more GPs than
required by the power calculation. The implementation design and accompanying evaluation is expected to deliver
vital insights into the specifics of implementing telemedicine in German routine care.
Trial registration: German Clinical Trials Register, DRKS00012944. Registered prospectively on 31 August 2017.
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Background
Teledermatology is the process of diagnosing dermato-
logic problems at a physical distance and, in the case of
store-and-forward technology, at different times [1].
Internationally, teledermatology is already implemented
in a number of healthcare systems [1]. For example, the
USA, the Netherlands and the United Kingdom (UK)
use teledermatology in clinical routine practice [1–3].
Dermatologic conditions are common in primary care
[4–6]. In about 80% of common conditions, the general
practitioner (GP) is able to make a diagnosis and initiate
treatment based on clinical examination and patient
history [7].
If a GP experiences diagnostic uncertainty or if treat-
ment fails, referral to a dermatologist is usually the next
step. Physical referrals are often associated with long
waiting times for an appointment. Long travel distance
between the patient’s home and the dermatologist’s
practice is another complication. Thus, teledermatology
is a viable alternative to physical referrals—especially in
rural areas.
According to previous studies, most common skin dis-
eases can safely be diagnosed by teledermatology [1]. A
randomized controlled trial by Whited et al. [8] showed
comparable clinical courses and quality of life in 392
patients. The study compared teledermatology with
physical referrals to dermatologists. Both patients and
care providers evaluated teledermatology positively [8].
Another randomized controlled trial by Eminovic et al.
[9] involved 631 patients. The study showed that 21% of
all physical referrals to dermatologists could be pre-
vented by teledermatology [9]. Other studies concluded
that between 18 and 94% (mean 43%) of physical derma-
tologist consultations could be prevented by telederma-
tology [1, 8, 10, 11]. Several studies showed that
teledermatology is equal to conventional referrals in
terms of accuracy, specificity, sensitivity and clinical
endpoints [1, 3, 11–15]. Depending on the health and
reimbursement system, teledermatology can lead to cost
savings up to 18% compared with conventional referrals
[1, 16]. Furthermore, a significant learning effect in GPs
was reported. This learning effect is presumed to con-
tribute to a sustainable cost reduction over time [16].
In Germany, however, teledermatology is not yet
implemented in routine care. The use of teledermatology
in general practice is restricted to local solutions and
pilot projects [2, 17]. Specialized first-line dermatologic
care in Germany is mainly provided by dermatologists
working in their own practices. Only a minority of der-
matologists work in hospitals. Thus, access to specialized
dermatologic care shows regional differences [18, 19].
Due to the growing number of patients and the relatively
difficult access to specialized dermatologic care, GPs will
play an increasingly important role in diagnosing and
treating dermatologic problems in the future [20].
Demographic change further contributes to the increas-
ing number of skin conditions and malignancies of the
skin [4, 20, 21]. Older patients have more difficulties
accessing specialized dermatologic care due to reduced
mobility [4]. To our knowledge, quite a few patients and
GPs in Germany help themselves by using commercial
end-to-end encrypted communication platforms such as
WhatsApp. Both patients and GPs send clinical data
such as dermatologic photographs, radiology images or
electrocardiogram (ECG) printouts to specialists to ob-
tain advice. The legality of these actions in the context
of rigorous German data protection laws is highly ques-
tionable. In summary, this background illustrates the
need for telemedicine as an addition to interdisciplinary
and cross-sectoral communication in German health
care.
Thus, the aim of our study is to evaluate the imple-
mentation of teledermatology in primary care in a
defined number of counties in Baden-Württemberg,
Germany.
Methods
Study design and setting
The study is planned as a cluster-randomized controlled
confirmatory study, where a county is regarded as one
cluster. The main scientific hypothesis is that the possi-
bility of store-and-forward teledermatology in GP
practices is going to reduce GP referrals to dermatolo-
gists by at least 15%. This protocol follows the Guidance
of Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Statement [22]. It
includes the schedule of enrolment and relevant assess-
ments (Fig. 1) using the SPIRIT figure template. A
SPIRIT checklist is provided in Additional file 1.
This project is one of the first to be supported by the
Federal Joint Committee’s Innovation Fund. In order to
facilitate innovations in German health care, the fund was
created in 2015 with the “Law on Strengthening Statutory
Health Care” (Gesetzliche Krankenversicherungs-Versor-
gungsstärkungsgesetz) [23]. The Federal Joint Committee
call for proposals is competitive and uses external peer
review. The sponsor has no influence over study design;
collection, management, analysis and interpretation of
data; writing of the report; and the decision to submit the
report for publication. Neither does the sponsor have
ultimate authority over any of these actions.
To describe the study setting, a short overview of the
health insurance system in Germany is presented. There
are around 116 statutory health insurance companies in
Germany. The Allgemeine Ortskrankenkasse (AOK) is
one of the largest statutory health insurance funds with
over 25 million insured persons (35% of all statutory in-
sured persons) [24]. Statutory insurance companies are
Koch et al. Trials          (2018) 19:583 Page 2 of 10
self-governed corporations under public law. The state
of Germany or federal regions may be shareholders in
these companies. They must provide health services for
everyone who is insured. They also must accept every
applicant for health services. Private health insurance
companies, on the other hand, are basically privately
owned.
In addition to their regular coverage, all health
insurance companies may sign direct contracts with GP
representatives and other specialist physician groups. An
example of such a contract is the Hausarztzentrierte
Versorgung (HzV) (GP-centered health care). Patients
enrolled in the HzV decide to enlist to one GP. Every
primary care physician has regular contracts with the
Association of Statutory Health Insurance Physicians
(KV). This association negotiates outpatient treatment
costs with the legislator and the insurance companies.
Within the regular contracts, the primary physician is
remunerated per consultation and treatment. In the case
of GP-centred care, the GP receives an additional
amount per capita directly from the insurance company.
The federal state of Baden-Württemberg is one of
Germany’s larger states with about 10 million inhabi-
tants. It is organized into several Landkreise (counties)
with variable population density, ranging from 3008
inhabitants per km2 in the urban region of Stuttgart to
101 inhabitants per km2 in the rural Main-Tauber
County [25]. Likewise, the number of dermatologists per
inhabitant varies from one statutory health insurance
(SHI) dermatologist per 9617 inhabitants (City of
Karlsruhe) to one dermatologist per 130,772 inhabitants
(Sigmaringen County) [26]. The SHI GP-to-inhabitant
ratio shows less variation: there is between one GP per
1070 inhabitants (Main-Tauber County) and one GP per
1501 inhabitants (Tuttlingen County) [26].
Eight counties were included in the study. Selection
criteria for the counties were the closeness to the study
center (Tübingen) and their similarity in study-relevant
indicators (see Table 1). These parameters will be used
for the counties’ matching and randomization process.
Allocation of patients to control or intervention groups
(−t2 in Fig. 1) is based on this randomization.
Fig. 1 SPIRIT 2013 figure with schedule of enrolment, interventions and assessments. GP general practitioner, HzV Hausarztzentrierte Versorgung
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Study design
During the first phase of the study (−t1 in Fig. 1), GP
teams will be recruited in the intervention counties.
Further preparations will include the preparation of data
protection policies and legal negotiations between insur-
ance companies, middleware providers and GPs. Next, a
run-in phase of 6 months will commence. In this phase,
the teledermatology system will be implemented in the
GP practices and GPs will be trained in the use of the
system.
After the run-in phase, 14 months after the beginning
of the study, the intervention phase will start. From this
point onward, patients can be enrolled (t0 in Fig. 1). The
phase will last 1 year. Then, a 10-month analysis and
publication phase will follow. See Fig. 2 for an overview.
The cluster level “county” is randomized into four
intervention and four control counties. In the interven-
tion counties, data from non-participating HzV practices
will serve as an internal control group at the cluster level
“practice”. At the cluster level “patient”, data from non-
participating patients are used as a second internal
control group. No blinding is applied to any level of the
trial. Figure 3 shows both study arms and an overview of
the different cluster levels.
The Institute of General Practice and Interprofessional
Care acts as the coordinating center and project lead. In
collaboration with the AOK, aQua and the Institute for
Clinical Epidemiology and Applied Biometry (IkEaB),
the institute also acts as the data management team.
Outcomes
The primary outcome measure is the number of conven-
tional referrals from GPs to dermatologists.
Secondary endpoints will be evaluated using a
mixed-methods approach. This will allow us to evaluate
different aspects of the implementation process. For in-
stance, the teledermatology system will provide informa-
tion about the referral time and process quality. This
data source is complemented by questionnaire surveys
from all participating groups. Both care providers (GPs,
dermatologists, GP practice staff ) and patients (telecon-
sultation patients and patients who have declined a tele-
consultations) will receive questionnaires on acceptance
and feasibility. Patient questionnaires will also include all
items from the Dermatology Life Quality Index (DLQI)
[27]. Semi-structured face-to-face interviews (n = 15
patients who have received a teledermatology referral
and n = 15 care providers, such as GPs, dermatologists
and GP practice staff ) will provide additional informa-
tion to the surveys. Lastly, a health economics analysis
based on routine data and support costs for the imple-
mentation of the teledermatology system is planned.
Table 1 Matching parameters of the eight study counties in the federal state of Baden-Württemberg
County Inhabitants per km2 Inhabitants Dermatologist:inhabitant ratio GP:inhabitant ratio
Böblingen 617 381,281 1:25,419 1:1352
Calw 195 155,359 1:51,786 1:1387
Esslingen 817 524,127 1:29,118 1:1368
Freudenstadt 133 116,233 1:58,117 1:1471
Reutlingen 274 282,113 1:18,808 1:1190
Rottweil 179 137,500 1:27,500 1:1127
Tuttlingen 186 136,606 1:27,321 1:1501
Zollernalbkreis 206 188,595 1:31,433 1:1266
GP general practitioner
Fig. 2 Project timeline of the 3-year project. GP general practitioner
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Study sites (GP practices) will be visited once during the
intervention phase by a study nurse for audit.
Details about the outcome parameters are presented in
Table 2.
Intervention (t1 in Fig. 1)
The intervention is the provision of all skills and equip-
ment needed to use teledermatology in general practice.
If a GP does not feel secure about the management of a
dermatologic case, he or she can use teledermatology.
Initially, the GP takes standardized pictures of the lesion
with a digital camera (Sony Cyber-shot DSC-W810).
Next, high-resolution close-up pictures of the lesion are
made using a polarized dermatoscope (MEDL4DW
DermaScope Polarizer). The GP then creates a telecon-
sultation. Case-relevant patient data from the patient
management system (PMS) are automatically included
using middleware. If needed, the GP may provide add-
itional case-relevant information such as the patient’s
medical history and a description of symptoms. This
information is then pseudonymized and transferred to a
server in the Netherlands (KSYOS teledermatology sys-
tem [3]). Dermatologists with teledermatology training
are then notified. If possible, the dermatologists diagnose
the lesion and recommend an appropriate course of
action. The thus completed report is then sent back to
the GP within 48 h. Both the data transfer and authenti-
cation use Secure Hypertext Transfer Protocol (https)
connections with 256-bit Secure Hash Algorithm (SHA)
encryption. An encrypted digital certificate is needed for
authentication.
If the information provided by the GP proves
insufficient, the dermatologist may either recommend a
physical referral to a dermatologist or initiate a “second
round”, in which the GP resends the case with possibly
better picture quality and more information on the case.
If malignant lesions are found, patients will be referred
to specialized dermatologic care. No other restrictions
concerning patient care are imposed on the GP teams.
Recruitment and study flow
The study contains a two-step enrolment process. The
first step is to recruit eligible GPs in the intervention
counties. Only HzV-contracted GPs will be included.
The GPs and their teams will then in turn recruit study
participants during the intervention phase (t0 in Fig. 1,
start 1 July 2018). The patient population of this study
comprises all HzV-enrolled, AOK-insured patients in the
eight counties. Patients must be at least 18 years of age.
Detailed inclusion and exclusion criteria and their role
in the recruitment process are shown in Fig. 4.
Study participants are allocated as follows. The family
doctors inform eligible patients (see Fig. 4 for criteria)
about the study and ask their written consent to par-
ticipate. After consent has been given and the teleder-
matology process has been completed, the family doctor
enters a value in the patient's PMS entry. This value is
visible in the subsequent data analysis and identifies the
patient as a study participant. Routine data from the
general practitioner's practice PMS are then transmitted
to the AOK quarterly via a secure data connection. The
AOK aggregates the data for the intervention and con-
trol circles.
No written consent is required from patients in the
control groups. When patients sign an HzV contract
with their insurance company, they consent to the
Fig. 3 Overview of clusters: different levels or clusters of the project. AOK Allgemeine Ortskrankenkasse, GP general practitioner, HzV
Hausarztzentrierte Versorgung
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anonymized analysis of their insurance data for scientific
and quality management purposes.
Candidates in the intervention group practices who do
not meet inclusion criteria (e.g., patients insured by
other statutory health insurances or not listed as HzV
patients) as well as patients refusing the intervention will
be treated as usual and referred to a dermatologist.
Eligible patients refusing the interventions will be
included in an internal control group (see Fig. 4).
Sample size calculation
The main scientific hypothesis is that the possibility of
teledermatology in general practice will reduce the
number of referrals to a dermatologist by 15% in the
intervention group. The statistical null hypothesis is a
reduction of 0%, the alternative is a reduction > 0%. The
basis of the sample size calculation is an assumed
reduction of 15%.
A mean of 120 referrals to dermatologists per year and
GP is assumed. In 2015, 40% of AOK-insured patients
were enrolled in the HzV [28, 29]. Thus, for the
subgroup of AOK patients, 48 dermatological referrals
per year and GP practice are to be expected in the
control population during the 1-year intervention phase
of the study. A Poisson distribution of the referrals for
each GP team is assumed. Furthermore, a type I error of
5% (two-sided) and a type II error of 20% are defined.
These assumptions lead to a calculation of 36 analyzable
GP teams (with, on average, 48 referrals per year and GP
practice each) per study arm. On the patient level, this
amounts to 1728 patients with the indication for a refer-
ral to a dermatologist in total. A 15% reduction equals
260 referrals in total. A 30% dropout buffer is taken into
account. The final sample size calculation amounts to
2400 patients with a reduction of 360 referrals.
Data analysis (t2 in Fig. 1)
The pooled routine dataset is sent from AOK to the
aQua institute. The aQua institute selects, filters and
anonymizes the data. Lastly, the aQua institute delivers
the anonymized patient dataset to the Institute for
Clinical Epidemiology and Applied Biometry (IKEaB) for
statistical analysis. All of these transfers use a secure,
encrypted protocol and are authenticated. The relevant
data sources are subject to extensive quality manage-
ment processes. To secure data protection of interview
and questionnaire data as well as process data from the
KSYOS system, the Tübingen University Hospital’s
(UKT) data protection agency is involved. They are inde-
pendent from the sponsor.
For the primary outcome, Poisson regression is chosen
as an analysis tool. To consider practice size and patient
load, the number of practice KV bills during the inter-
vention phase is applied as an offset. The dichotomous
factor “study arm” is applied for the calculation. The
GPs are the unit of observation. For both study arms,
Table 2 Primary and secondary endpoints, data sources and evaluation methods
Secondary endpoints (intervention group) Primary endpoint (both groups)
Patients GPs Dermatologists GP team
staff
Teledermatology
software/KSYOS
(process evaluation)
Routine data
Care provider/customer satisfaction, description of technical processes with their
advantages and disadvantages
• Number of
teleconsultations
• Time until
dermatologist
answers
• Number of physical
referral
recommendations
• Number of queries
by dermatologists
after
teleconsultation
• Type of disease
treated by
teleconsultation
• Duration of
complete
teleconsultation
process
• Result of
dermatologic
consultation
• Number of referrals to
dermatologists by GPs
• Ambulatory dermatologic
diagnoses
• Ambulatory patient contacts with
GPs and/or dermatologists due to
skin conditions (including EBMa
keys)
• Number of clinic referrals due to
skin conditions
• Quality of life (DLQI,
questionnaire)
• Satisfaction with
dermatologic care/
telemedicine
(questionnaire,
interviews)
Appraisal of feasibility, practicability and barriers for
implementation (interviews)
• Number of reports by
dermatologists after
consultation (KSYOS
and GP PMS)
• Time until
dermatologist report
completed (PMS)
• Recommendation of
physical referrals by
teledermatologists
DLQI Dermatology Life Quality Index, EBM Einheitlicher Bewertungsmaßstab, GP general practitioner, KSYOS teledermatology system, PMS patient management software
aPhysician’s fee table used to encode what kind of procedure is performed in an outpatient setting and how much money will be paid for it; data are transferred
from a practice to the Kassenärztliche Vereinigung and then generate a defined amount of income for the physician
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separate confidence intervals are created for the number
of referrals per KV bill.
For the sample size calculation, a simple t test was
used. In contrast to the sample size calculation, the stat-
istical analysis will use a more complex method (Poisson
regression). This is expected to lead to an increased
power of the study, because the offset “total number of
KV bills during intervention” explains parts of the vari-
ability between GP teams. Study power should thus be
over 80%. Primary analysis will be calculated as a Poisson
regression with a significance level of 5% (two-sided).
Analogous methods will be applied to secondary out-
comes (see later). However, the interpretation of local
significances is not designed to be strictly confirmatory.
Due to the multitude of secondary parameters lacking
hierarchical structure, a correction for multiple tests is
unrealistic. Descriptive analyses are performed following
scaling and observed data distribution.
Secondary outcomes are analyzed using adequate re-
gression models (linear, ordinal, logistic, multinominal)
and considering cluster effects. The generalized estimat-
ing equations (GEE) method is employed. For GP
team-related analyses (unit of observation = GP), appro-
priate regression models without cluster adjustment are
used, because the outcome is only measured once per
GP team. This is especially true for analyses based on
KSYOS data (process data) and AOK insurance data.
The same applies for secondary endpoint analyses
among dermatologists, GPs and nonphysician staff.
Questionnaires will be piloted using the “think aloud”
method [30]. During the pilot, some participants
(patients and care providers) are asked to read question-
naire items and voice their thoughts on them. A re-
search team member observes the participants and
creates a protocol. The protocols of these observations
are then used to improve the questionnaire.
Interviews are transcribed and then analyzed using
qualitative content analysis [31]. Analysis will continue
until thematic saturation is reached. The resulting
category system will provide information additional to
the questionnaire data and help understand patients’ and
care providers’ perspectives on teledermatology.
Ancillary studies may include analysis of anonymized
process data and/or anonymized pictures of lesions.
Design and planning will be presented in separate
publications.
Health economic analysis
Additionally, a health economic analysis will be
conducted (t2 in Fig. 1). The evaluation shall provide an
Fig. 4 Recruitment and flow. Flow diagram (adapted and modified from the CONSORT statement) demonstrating how the two-step recruitment
process and patient flow work. AOK Allgemeine Ortskrankenkasse, CONSORT Consolidated Standards of Reporting Trials, GP general practitioner,
HzV Hausarztzentrierte Versorgung
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estimate of the marginal cost advantage of telederma-
tology referrals compared to conventional referrals.
Furthermore, conclusions may be drawn as to which
parameters offer particularly high marginal cost advan-
tages. This is of crucial importance, particularly with re-
gard to the transferability of such interventions to other
specific fields and regions.
Under the assumption of comparable effects between
teledermatology and conventional referrals, a cost
minimization analysis will be pursued for health eco-
nomic evaluation [32]. For this purpose, the quantity
structure of costs and the costs of the teledermatology
intervention as well as the conventional treatment will
be constructed. The health economic evaluation will
consider two cost perspectives separately. In the first
scenario, only the costs incurred to the SHI will be
accounted for; while in the second scenario, the societal
costs will be examined to illustrate the cost difference
for the SHI and the society as a whole. The costs of
implementation, treatment and diagnostics for GPs
and dermatologists will be considered in the cost
minimization analysis of both scenarios. In the analysis
from an overall social perspective, the travel times and
costs to patients will additionally be taken into ac-
count. The routine data of AOK Baden-Württemberg
will serve as the data source for the evaluation. Fur-
thermore, costs related to the intervention, such as the
costs of technical equipment and training, will be col-
lected and analyzed.
Discussion
We present the study protocol of a cluster-randomized
clinical trial aiming at implementing teledermatology
into general practice in Germany. Internationally,
teledermatology is established in general practice as a
safe and cost-effective way to treat patients with derma-
tologic problems. Cost savings and benefits for patients
are especially pronounced in rural areas with long
distances to dermatologists. So far, only a few projects
using store-and-forward technology have tried to estab-
lish teledermatology in German health care. None of
these projects have transferred into routine care. There
are numerous reasons that contribute to the difficulties
in implementing telemedicine in general in the German
health care system. Understanding their implications for
our study and considering them in planning and
conducting the study is thus important for its success.
One reason contributing to the difficulties in imple-
menting telemedicine is the rather restrictive data
protection laws in Germany. Data protection and owner-
ship are culturally valued topics in Germany. Thus,
German data protection laws guarantee high data safety
for patients, while providing little room for innovation,
even in scientific settings or pilot studies. This is evident
when comparing the German situation to the
Netherlands or the Scandinavian countries, where a
more centralistic and less restrictive data protection
culture prevails. GPs and patients might therefore
choose not to participate or to drop out of the study due
to data safety concerns. In our study, we provide
information to all participants about data safety and
protection. All study partners have agreed on a data
protection policy that follows EU regulations.
Another challenge for the implementation of telemedi-
cine in German primary care is the heterogeneity of prac-
tices. Basically each aspect of daily work (team structure,
patient management software, size of the practice, practice
organization) is different between practices [33]. For
example, about 235 different digital patient data manage-
ment systems exist in Germany [34]. In 2017, German law
enforced the implementation of a generic patient data
interface within 2 years [35]. Using such an interface is
currently the only way to export patient data to
third-party solutions, like the KSYOS teledermatology sys-
tem. Nevertheless, there still are some PMSs that do not
support such an interface or ask for licensing and support
fees. The GP may use the teledermatology nevertheless by
manually importing and exporting data, but that might
prove too time-consuming for daily practice. The conse-
quence might be that the GP drops out of the study.
To ensure the intervention’s success, GPs must be
allowed to choose their own way of implementing the
intervention in their practice. Thus, it is allowed for GPs to
delegate parts of the teledermatology procedure (e.g., pho-
tography of the skin lesions) to practice staff. This way, the
acceptance of the intervention hopefully increases, thus
resulting in more realistic and reliable results.
In order to grasp the multitude of different perspectives,
a mixed-methods evaluation was designed. We hope to
identify relevant barriers and enablers for the implementa-
tion of sustainable teledermatology in routine general
practice. If we succeed, the TeleDerm study could be a
milestone in the implementation of telemedicine in gen-
eral and teledermatology in particular in Germany.
Strengths and limitations
The heterogeneity of GP practices, as stated earlier, is
one of the major challenges of the study. We expect this
to have an impact on the activity of the referring GPs.
Therefore, we will recruit 30% more GPs than needed
for statistical power to suffice. The internal control
group allows us to examine cluster effects.
During the run-in phase of 6 months, first experiences
with the technical implementation and the application of
the teledermatology system in daily practice are made.
This information will allow adjustments of the imple-
mentation processes in the GP practices. Also, we aim to
address possible data safety concerns on all sides (GPs,
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patients, AOK). Experiences collected during run-in will
be used to constantly inform and improve the ongoing
implementation process.
An advantage of this study is that GP participants
need little extra training. The intervention is tailored
and very close to the reality of routine general practice
in Germany. This, with the gained experiences from the
study, will help to facilitate a bigger roll-out of teleder-
matology in German general practice in the future. To
enable and plan a large-scale roll-out is a prerequisite
for the funding for this study.
Our design allows us to collect information that has an
impact from the implementation into routine care such as
acceptance among patients and GPs. If the study succeeds,
it will be the first teledermatology store-and-forward
project to actually pass the barrier from a research project
into daily practice, thus reaching new horizons for the
much anticipated advance of eHealth in Germany.
Trial status
At the time of manuscript submission, the study design
has been evaluated by an independent international
reviewer and has been approved by the responsible
ethics committee of the UKT. Recruitment and enrol-
ment of patients started in July 2018.
Protocol version and history
Current: Version 2, 9 August 2017. Past: Version 1, 16
June 2017.
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Additional file 1: SPIRIT 2013 checklist. (DOC 123 kb)
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